Biopharmaceuticals company DISCO Pharmaceuticals has entered an exclusive license agreement with biotech company Amgen to advance novel cancer targeted therapies.  The companies aim to develop the therapies for a target mapped on the surface of a cancer cell by DISCO’s proprietary platform.  Under the terms of the agreement, DISCO will be eligible to receive up […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!